噻托溴铵联合沙美特罗／丙酸氟替卡松治疗稳定期中重度COPD的临床疗效分析

摘要

Objective:To explore the clinical effect of drug combination therapy on moderate -severe COPD at stable stage.Methods:120 patients with moderate-severe COPD at stable stage were randomly divided into the control group and the observation group .The patients in the control group were given salmeterol/fluticasone propionate, and those in the observation group were given tiotropium bromide additionally on basis of the control group.Results:The pulmonary function (FVC, FEV1, FEV1 %Pred and FEV1/FVC) of patients in the observation group were sig-nificantly improved after treatment .Compared with that in the same group before treatment and in the control group after treatment , there was signif-icant difference ( P <0.05).6MWT in the two groups was significantly extended than that in the same group before treatment ( P <0.05).The score of each factor in the SGRQ questionnaire scale of the two groups after treatment was significantly lower , and there was significant difference in the score before and after treatment ( P <0.05).Conclusions:The application of tiotropium bromide combined with salmeterol /fluticasone propi-onate to moderate-severe COPD at stable stage can effectively improve the respiratory function and the living quality of patients .%目的：探讨联合用药治疗稳定期中重度COPD患者的临床效果。方法：选取稳定期中重度COPD患者120例，随机分为两组。对照组单纯给予沙美特罗／丙酸氟替卡松治疗，观察组在对照组基础上给予噻托溴铵治疗。结果：观察组患者肺功能指标 FVC、FEV1、FEV1％Pred、FEV1／FVC在治疗后均有明显改善，与同组治疗前和对照组治疗后比较，差异均有统计学意义（ P ＜0．05）；对照组和观察组患者6 MWT均较同组治疗前明显延长（ P ＜0．05）；治疗后两组患者圣乔治呼吸问卷（ SGRQ）调查量表各因子得分均明显降低，治疗前后比较，差异具有统计学意义（ P ＜0．05）。结论：对稳定期中重度 COPD患者实施噻托溴铵联合沙美特罗／丙酸氟替卡松治疗，可以有效改善患者呼吸功能，提高患者生活质量。